Medibank (ASX:MPL) share price lifts despite rumours of failed hospital bid

Here are all the details on Medibank's supposed failed acquisition.

| More on:
Private health insurance diagram.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Medibank share price is up 0.7% today, trading at $3.23
  • That's despite reports the company's rumoured acquisition of a stake in Cura Group has failed
  • It was previously reported the insurer was planning to announce the purchase before the release of its half year results

The Medibank Private Ltd (ASX: MPL) share price is in the green today despite talk its bid for day hospital operator Cura Group, has fallen through.

Previously, it was reported the private health insurer might have been gearing up to release news of the acquisition in time for its half year results – set to drop next Friday.

At the time of writing, the Medibank share price is $3.23, 0.78% higher than its previous close.

For comparison, the S&P/ASX 200 Index (ASX: XJO) has slipped 0.8% this morning.

Let's take a look at the latest rumours surrounding Medibank.

Medibank's rumoured acquisition falls through

The Medibank share price appears unfazed by rumours its acquisition of private day hospital asset Cura has failed.

The private insurer was previously reported to have agreed to buy a stake in the business for an undetermined amount.

However, The Australian today reported the deal has been abandoned prior to settling.

Cura owns day hospitals in every Australian state and in the Australian Capital Territory (ACT).

Its crown jewels include Barton Private Hospital, Sydney Day Surgery Prince Alfred, and Somerset Private Hospital.

According to the publication, while the proposed acquisition's cost was unknown, when Fresenius Medical Care purchased its majority holding in Cura – reported to be 70% – in 2017, it valued the hospital operator at $400 million.

While the publication didn't confirm how big of a stake in Cura that Medibank was rumoured to be purchasing, Fresenius Medical Care hit back at initial reports it was offloading any of its stake. The company said:

Fresenius Medical Care is strongly committed to long-term ownership and continues to be deeply invested in growing the Cura Day Hospitals business. There is no plan to change this approach in the foreseeable future.

Medibank share price snapshot

While it's gaining today, this year so far has been rough on the Medibank share price.

It has fallen 5% since the start of 2022.

Though, it's currently 14% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Why are Mesoblast shares jumping 10% to a 52-week high?

This biotech is hitting new highs on Friday. Let's find out why.

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Ansell shares tumble to a 3-month low. Is this a buying opportunity?

Ansell shares have slid to a 3-month low. Could oversold signals point to a buying opportunity for long-term investors?

Read more »

Female scientist working in a laboratory.
Healthcare Shares

These three biotechs show how the sector can produce huge outsized gains, but are they still good value?

These drug developers' shares are trading near 12-month highs.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

This biotech is approaching 20-bagger status within a year and the good news continues to come

This company has just won approval to go ahead with a key clinical trial.

Read more »

An investor sits at a table in front of her laptop with a party hat on her head and a cake next to her symbolising new year's eve but the 4DS Memory share price is plunging so she looks very disappointed and depressed
Healthcare Shares

$5 billion ASX 200 healthcare stock tumbling on CEO exit

Investors are bidding down the ASX 200 healthcare giant on Thursday. Let’s see why.

Read more »

woman testing substance in laboratory dish, csl share price
Share Market News

After a 73% surge this ASX healthcare share looks far from done

Brokers are upbeat, and some see possible gains of 90% in 2026.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which biotech's shares are surging higher on US patent news?

Investors like what they see from this drug company.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Read more »